Vaccine Adjuvants Market Size And Forecast By Type (Pathogen, Adjuvant Emulsion, Particulate), By Route of Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, And Trend Report

Vaccine Adjuvants Market Size And Forecast By Type (Pathogen, Adjuvant Emulsion, Particulate), By Route of Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, And Trend Analysis, 2014 - 2025

Published: September 2017  |  90 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-612-7

Industry Insights

The global vaccine adjuvants market size was valued at USD 308.99 million in 2016 and is anticipated to grow with a CAGR of 10.6%. Rising prevalence of cervical cancer, infectious diseases such as Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases is expected to boost the demand for adjuvants.

In addition, growing focus on long-lasting effect of immunization against existing and emerging diseases is expected to boost demand for adjuvants. The importance of adjuvant research for development of these products has increased significantly due to inadequate immunogenicity of innovative vaccine antigens. Moreover, the increasing use of recombinant and synthetic vaccines is expected to accelerate growth of this market in the coming years.

U.S. vaccine adjuvants market, by type, 2014 - 2025 (USD Million)

U.S. vaccine adjuvants market

Major players are engaged in the discovery and development of new adjuvants to treat fatal diseases. Products under clinical trials include AS01, ISCOM & ISCOMMATRIX, and AS02, and presence of these pipeline drugs is estimated to further boost the market.

The U.S. is a developed country with a huge population and large number of travelers visit the country, which results in increase in need of immunization for safety of the local population. In addition, rise in favorable government initiatives for immunization of people against serious diseases is anticipated to boost the market. For instance, the National Institute of Allergy and Infectious Diseases initiated a program for advancements in adjuvants for human use.

Type Insights

On the basis of type, vaccine adjuvants market is segmented into pathogen, adjuvant emulsion, particulate, combination, and others. Among these, particulate type held the largest market share in 2016, followed by adjuvant emulsion. This large share can be attributed to the presence of wide range of products and greater efficiency against the diseases.

Particulate type includes adjuvants consisting of alum, virosomes, and cytokines. Alum is the most commonly used adjuvant consisting of aluminum salts. It is basically used in hepatitis B and HPV vaccines. Virosomes that are particles resembling noninfectious viruses are used as adjuvants in hepatitis A, Epaxal and influenza vaccine Inflexal.

On the other hand, pathogen type segment is expected to be the fastest growing over the forecast period. Some pathogenic adjuvants tested include monophosphoryl lipid A. It is combined with alum to produce AS04 adjuvant used in an HPV-Cervarix.

Application Insights

Infectious diseases accounted for the largest share in the vaccine adjuvants market. This large share can be attributed to gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others. In addition, the presence of strong pipeline products for vaccine adjuvants related to infectious diseases is anticipated to fuel the market growth in the coming years. This includes CpG (TLR 9 agonist) vaccine adjuvant from InvivoGen. The product is in phase 3 of clinical trial and provides CD8 T cell-mediated immunity and Th1-type immunity.

Cancer is identified to be the fastest growing application segment due to its high prevalence and ongoing R&D for targeted therapy for various types of cancers. Moreover, increasing use of adjuvants, such as Cervarix, is further anticipated to fuel growth.

Administration Type Insights

On the basis of route of administration, adjuvants are categorized into oral, intradermal, intranasal, intramuscular, and others. The intramuscular segment accounted for the largest market share in 2016 due to better immune specificity. These include vaccines for HPV, influenza, meningitis, etc. The efficacy of vaccines depends on the route of administration. For instance, alum salts, which are the most widely used parenteral adjuvants, are ineffective when administered by the oral or nasal route.

On the other hand, intradermal route is expected to be the fastest growing segment due to longer absorption time and duration of action as compared to other routes, which increases the demand for vaccines administered through this route. Some adjuvants, such as TLR3-Ligand Poly (I:C), induce mucosal antibody responses and protect against genital HSV-2 infection when administered intradermally.

Global vaccine adjuvants market by region, 2016 (%)

Global vaccine adjuvants market

Regional Insights

North America held the largest market share in 2016 followed by Europe. The factors contributing to growth of vaccine adjuvants market in the North American region are rise in investments for R&D of new therapeutics and increase in fatal epidemic diseases. Thus, leading to the need for immunization against acute and chronic diseases. In addition, local presence of key market players in the U.S. increases the penetration of products. For instance, Adjuvance Technologies, Inc. has developed portfolio of adjuvants targeted toward treatment of various diseases.

Asia Pacific was estimated to be the fastest growing market due to the continuously improving healthcare facilities, including availability of medicines, coupled with rising R&D funding to meet the huge unmet demands. This is expected to increase the revenue share over the forecast period.

Competitive Insights

Some of key participants in the market are GlaxoSmithKline plc.; Novavax, Inc.; Adjuvance Technologies, Inc.; SPI Pharma.; Agenus, Inc.; CSL Limited; InvivoGen; and Brenntag Biosector.

These market players are focusing on expanding their businesses in developing regions to increase their market share. Furthermore, they are adopting strategies such as collaborations, mergers & acquisitions, and new product development. For instance, in July 2017, GSK collaborated with Exscientia to develop new drugs.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million & CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, & MEA

Country scope

U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the industry trends in each of the sub segment from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the vaccine adjuvants market on the basis of type, application, route of administration, and region: 

  • Product Type Outlook (Revenue, USD Million; 2014 - 2025)

    • Pathogen

    • Adjuvant Emulsion

    • Particulate

    • Combination

    • Others

  • Application Outlook (Revenue, USD Million; 2014 - 2025)

    • Infectious Disease

    • Cancer

    • Others

  • Administration Type Outlook (Revenue, USD Million; 2014 - 2025)

    • Oral

    • Intradermal

    • Intranasal

    • Intramuscular

    • Others

  • Regional Outlook (Revenue, USD Million; 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA